There's More to This Company Than Marijuana

Since last summer, enthusiasm surrounding marijuana's potential as a treatment for epilepsy has led to investors more than doubling their money in Insys Therapeutics (NASDAQ: INSY  ) .

Insys Therapeutics is one of the only publicly-traded companies pursuing the development of prescription drugs based on the chemical cannabinoids found in marijuana, but the reasons for owning shares in the company stretch far beyond its marijuana program.

Building a foundation
While competitors such as GW Pharmaceuticals are fully focused on developing marijuana medicines, Insys Therapeutics is also working on a slate of non-marijuana therapies.

Insys already markets Subsys, an oral spray formulation of the opioid fentanyl. The drug's ease in dosing and rapid onset have made it the top-selling fentanyl product on the market for managing chemotherapy pain. Last year, Subsys' sales grew 124% to $219.5 million; that momentum carried over...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.fool.com/investing/general/2015/05/09/theres-more-to-this-company-than-marijuana.aspx